TNFRSF17 and Miyoshi myopathy: In recent years, B-cell maturation antigen (BCMA)-directed therapies, including antibody-drug conjugates, chimeric antigen receptor (CAR) T-cells, and bispecific antibodies (BsAbs), have offered a new era of hope to patients with relapsed or refractory MM (RRMM).